Agios Pharmaceuticals (AGIO) News Today $53.78 -1.62 (-2.92%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest UpdateAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 4,340,000 shares, a growth of 5.6% from the October 15th total of 4,110,000 shares. Based on an average daily trading volume, of 524,700 shares, the short-interest ratio is presently 8.3 days. Currently, 7.9% of the company's stock are sold short.November 17 at 1:45 AM | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Moderate Buy" from AnalystsAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and four have assigned aNovember 16 at 5:06 AM | marketbeat.comLeerink Partners Sticks to Their Hold Rating for Agios Pharma (AGIO)November 13, 2024 | markets.businessinsider.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by StockNews.comNovember 11, 2024 | americanbankingnews.comStockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to HoldStockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday.November 9, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good NewsNovember 7, 2024 | finance.yahoo.comAgios Pharmaceuticals to present new data on mitapivat, tebapivatNovember 7, 2024 | markets.businessinsider.comAgios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and ExpositionNovember 5, 2024 | globenewswire.comAssenagon Asset Management S.A. Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Assenagon Asset Management S.A. lowered its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 94.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,409 shares of the biophaNovember 4, 2024 | marketbeat.comBank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO)November 2, 2024 | markets.businessinsider.comAgios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagNovember 2, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | msn.comAgios Pharmaceuticals Reports Robust Q3 2024 ResultsNovember 2, 2024 | markets.businessinsider.comAgios Pharmaceuticals price target raised to $53 from $51 at ScotiabankNovember 2, 2024 | markets.businessinsider.comAgios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.comStockNews.com downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday.November 1, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Earns "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research report on Friday.November 1, 2024 | marketbeat.comScotiabank Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) StockScotiabank lifted their price target on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a "sector outperform" rating in a report on Friday.November 1, 2024 | marketbeat.comCognex (CGNX) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comAgios Pharma: Buy Rating Backed by Strong Financial Performance and Promising Clinical OutcomesNovember 1, 2024 | markets.businessinsider.comDoorDash Inc Q3 Earnings SummaryOctober 31, 2024 | markets.businessinsider.comAgios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | seekingalpha.comAgios Reports Business Highlights and Third Quarter 2024 Financial ResultsOctober 31, 2024 | globenewswire.comAgios Pharmaceuticals Q3 2024 Earnings PreviewOctober 30, 2024 | msn.comFY2025 Earnings Estimate for AGIO Issued By Leerink PartnrsAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Equities researchers at Leerink Partnrs raised their FY2025 earnings estimates for Agios Pharmaceuticals in a research note issued on Monday, October 28th. Leerink Partnrs analyst A. Berens now expects that the biopharmaceutical company wiOctober 30, 2024 | marketbeat.comZacks Research Has Negative Forecast for AGIO Q3 EarningsAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Research analysts at Zacks Research reduced their Q3 2025 earnings estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now expects that theOctober 25, 2024 | marketbeat.comAgios Pharmaceuticals (AGIO) to Release Quarterly Earnings on ThursdayAgios Pharmaceuticals (NASDAQ:AGIO) will be releasing earnings before the market opens on Thursday, October 31, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=636634)October 24, 2024 | marketbeat.comAgios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell DiseaseOctober 23, 2024 | markets.businessinsider.comAgios Pharmaceuticals completes enrollment of Phase 3 RISE UP studyOctober 23, 2024 | markets.businessinsider.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight analysts that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and four have assignedOctober 22, 2024 | marketbeat.comAGIO Agios Pharmaceuticals, Inc.October 17, 2024 | seekingalpha.comAgios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024October 17, 2024 | globenewswire.comAgios Pharmaceuticals (NASDAQ:AGIO) Upgraded by StockNews.com to HoldStockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday.October 16, 2024 | marketbeat.comScotiabank Initiates Coverage of Agios Pharmaceuticals (AGIO) with Sector Outperform RecommendationOctober 16, 2024 | msn.comScotiabank Begins Coverage on Agios Pharmaceuticals (NASDAQ:AGIO)Scotiabank started coverage on shares of Agios Pharmaceuticals in a research note on Wednesday. They issued a "sector outperform" rating on the stock.October 16, 2024 | marketbeat.comLeerink Partners Reaffirms Their Hold Rating on Agios Pharma (AGIO)October 15, 2024 | markets.businessinsider.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 10.1% in SeptemberAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 3,280,000 shares, a growth of 10.1% from the September 15th total of 2,980,000 shares. Approximately 6.0% of the company's shares are sold short. Based on an average daily volume of 503,300 shares, the short-interest ratio is currently 6.5 days.October 15, 2024 | marketbeat.comSG Americas Securities LLC Acquires New Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)SG Americas Securities LLC purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,864 shares of the biopharmaceutical company's stock,October 14, 2024 | marketbeat.comAQR Capital Management LLC Increases Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)AQR Capital Management LLC lifted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 196.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 33,164 shares of the biopharmaceutical company's stock after purchasing an additional 21,980 shareOctober 11, 2024 | marketbeat.com4 Analysts Have This To Say About Agios PharmaceuticalsOctober 10, 2024 | benzinga.comAgios Pharmaceuticals' (AGIO) "Outperform" Rating Reaffirmed at Raymond JamesRaymond James reaffirmed an "outperform" rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday.October 10, 2024 | marketbeat.com23,378 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Bought by Sei Investments Co.Sei Investments Co. acquired a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 23,378 shares of the biopharmaceutical company's stock,October 8, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Has $5.94 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)The Manufacturers Life Insurance Company raised its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 54.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 137,844 shares of the biOctober 7, 2024 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones Sells 2,542 SharesOctober 1, 2024 | insidertrades.comFrazier Life Sciences Management L.P. Has $37.60 Million Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Frazier Life Sciences Management L.P. grew its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 66.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 871,974September 29, 2024 | marketbeat.comLeerink Partners Downgrades Agios Pharmaceuticals (AGIO)September 28, 2024 | msn.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Axa S.A.Axa S.A. lessened its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 10.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 238,682 shares of the biopharmaceutical company's stock after selling 26,September 28, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Santhera Pharmaceuticals Holding (OtherSPHDF) and Agios Pharma (AGIO)September 27, 2024 | markets.businessinsider.comAgios Pharma’s Market Prospects Bolstered by Reduced Competition and Positive Drug Development OutlookSeptember 27, 2024 | markets.businessinsider.comMicron To $150? Here Are 10 Top Analyst Forecasts For FridaySeptember 27, 2024 | benzinga.comThis HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For FridaySeptember 27, 2024 | benzinga.com Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address How one pattern has averaged an 85% return per year since the pandemic. (Ad)Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern… Follow this link here and enter your email address to sign up… AGIO Media Mentions By Week AGIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGIO News Sentiment▼0.410.55▲Average Medical News Sentiment AGIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGIO Articles This Week▼64▲AGIO Articles Average Week Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Jazz Pharmaceuticals News Vaxcyte News Dr. Reddy's Laboratories News Sarepta Therapeutics News Catalent News Revolution Medicines News Qiagen News Intra-Cellular Therapies News Roivant Sciences News Viking Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGIO) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGIO Stock Alerts